fda safety communication semaglutide vision loss naion 2025 New lawsuits claim that certain GLP-1 medications may be linked to sudden loss. Patients across the United States say they developed a rare optic nerve condition called NAION, which can reduce GLP-1 medications and eye problem

A study of 8,000 people showed: People who stayed on the medicine lost about 12% in 1 year People who stopped early lost only about 3.6% Why the difference

Aib 13 GLP-1, GIP, GCG (glucagon), and GLP-2 share high homology so that it ought to be considered that GCGR and GLP-2R should sidestep the activation of the designed GLP-1/GIP dual agonist

importante observar que a semaglutida no adequada para todos os pacientes com DM2 e deve ser prescrita por um mdico com base nas necessidades e histrico mdico individuais

Respecte les peaux sensibles grce sa composition dorigine biologique

Healthcare providers should consider individual patient lifestyles, routines, and ability to adhere to treatment regimens when prescribing semaglutide